Yazar "Turan, Muzaffer Onur" için listeleme
-
Chronic obstructive pulmonary disease phenotypes in Turkey: The COPET study-a national, multicenter cross-sectional observational study
Yazar, Esra Ertan; Yiğitbaş, Burcu Arpınar; Öztürk, Can; Çalıkoğlu, Mukadder; Gülbaş, Gazi; Turan, Muzaffer Onur; Sarıoğlu, Nurhan (Scientific and Technological Research Council Turkey, 2022)Background/aim: While mortality rates decrease in many chronic diseases, it continues to increase in COPD. This situation has led to the need to develop new approaches such as phenotypes in the management of COPD. We aimed ... -
Evaluation of vitamin B12 and D, folic acid and homocystein levels in stable COPD patients
Turan, Muzaffer Onur; Sarıoğlu, Nurhan; Turan, Pakize Ayşe; Özdemir, Özer; Fazlıoğlu, Nevin; Köseoğlu, Mehmet; Özkanay, Hayat; Güney, Özgür (European Respiratory Soc Journals Ltd, 2020)Introduction: As COPD is a disease with malnutrition, catabolic process and chronic inflamation, vitamin deficiency may be seen frequently in COPD patients. We aimed to evaluate the levels of vitamin B12 and D, folic acid ... -
Long acting B-2 agonists (LABA) or anticholinergics (LAMA): Which one is more efficient in Group A COPD patients?
Turan, Muzaffer Onur; Ogan, Nalan; Bozkuş, Fulsen; Sarıoğlu, Nurhan; Turan, Pakize Ayşe; Satıcı, Celal (European Respiratory Soc Journals Ltd, 2021)Introduction: Long-acting anticholinergic (LAMA) or beta-2 agonists (LABA) for symptom control in symptomatic group A COPD patients in GOLD guideline, however, there is no mention of priority or superiority between the two ... -
Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): Which one may be the first option in group A COPD patients?
Turan, Muzaffer Onur; Ogan, Nalan; Bozkuş, Fulsen; Sarıoglu, Nurhan; Turan, Pakize Ayşe; Satıcı, Celal (Springer Heidelberg, 2024)IntroductionLong-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) have been recommended for symptom control in group A COPD patients as a first-line bronchodilator treatment in GOLD guidelines. However, there ...
